We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00940576
First Posted: July 16, 2009
Last Update Posted: May 25, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
German Federal Ministry of Education and Research
Information provided by (Responsible Party):
Gerhard Jahreis, University of Jena
Results First Submitted: July 17, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Ulcerative Colitis
Crohns Disease
Interventions: Dietary Supplement: mare´s milk
Other: placebo drink

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Oral Intake of Mare´s Milk First, Then Placebo Oral Intake of 250 ml per day Mare´s Milk First, Then 250 ml per day Placebo
Oral Intake of Placebo First, Then Mare´s Milk Oral intake of 250 ml per day placebo first, then 250 ml per day mare´s milk

Participant Flow:   Overall Study
    Oral Intake of Mare´s Milk First, Then Placebo   Oral Intake of Placebo First, Then Mare´s Milk
STARTED   8   9 
COMPLETED   8   9 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Study Participants Oral intake of placebo first, then mare´s milk and oral intake of mare´s milk first, then placebo respectively.

Baseline Measures
   All Study Participants 
Overall Participants Analyzed 
[Units: Participants]
 17 
Age 
[Units: Participants]
 
<=18 years   15 
Between 18 and 65 years   2 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 19.0  (8.4) 
Gender 
[Units: Participants]
 
Female   10 
Male   7 
Region of Enrollment 
[Units: Participants]
 
Germany   17 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Score of Crohn´s Disease and/or Ulcerative Colitis   [ Time Frame: 8 weeks ]

2.  Secondary:   Extra-intestinal Pain   [ Time Frame: 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Gerhard Jahreis, Prof. Dr.
Organization: University of Jena, Institute of Nutrition, Department of Nutritional Physiology Jena, Thuringia, Germany
phone: +(49)3641/949610
e-mail: gerhard.jahreis@uni-jena.de



Responsible Party: Gerhard Jahreis, University of Jena
ClinicalTrials.gov Identifier: NCT00940576     History of Changes
Other Study ID Numbers: LSEP_H08b-00
First Submitted: July 15, 2009
First Posted: July 16, 2009
Results First Submitted: July 17, 2009
Results First Posted: April 20, 2015
Last Update Posted: May 25, 2015